Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Human genetic evidence challenges NCOA1 as a monogenic obesity gene.

Created on 09 Oct 2026

Authors

Jérôme Delplanque, Audrey Leloire, Lauriane Le Collen, Hélène Loiselle, Bénédicte Toussaint, Emmanuel Vaillant, Frédéric Allegaert, Timothée Beke, Guillaume Charpentier, Sylvia Franc, Beverley Balkau, Michel Marre, Emma Henriques, Emmanuel Buse Falay, Mehdi Derhourhi, Philippe Froguel, Amélie Bonnefond

Published in

Cell reports. Medicine. Pages 103106. Oct 08, 2026. Epub Oct 08, 2026.

Abstract

Obesity is a heterogeneous disease with a substantial genetic component. Rare pathogenic variants in genes of the leptin-melanocortin pathway can cause monogenic obesity and support targeted therapies such as setmelanotide, a melanocortin 4 receptor agonist. Pathogenic variants in NCOA1, encoding the nuclear receptor co-activator SRC-1, have recently been proposed as a cause of monogenic obesity through impaired leptin-induced POMC activation, leading to the inclusion of NCOA1 variant carriers in the EMANATE setmelanotide trial. However, despite biological rationale, the contribution of NCOA1 variants to human obesity remains elusive. Here, we assess NCOA1 variants with case-control analyses in adults and children from the RaDiO study, combined with in vitro assays and replication in the UK Biobank. We find no association between pathogenic NCOA1 variants and obesity or body mass index.

PMID:
42849447
Bibliographic data and abstract were imported from PubMed on 09 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 16
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement